Pluvicto Now Approved for Hormone-Sensitve #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRI @ThePCRI
Pluvicto Now Approved for Hormone-Sensitve #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRI  @ThePCRI
Uploaded October 2026 | Updated November 2026, 3 hours ago
To learn more about prostate cancer, visit pcri.org

00:00 Introduction
00:30 What is Pluvicto and how does it work?
01:15 Do non-hormone-resistant patients on Pluvicto need hormone therapy?
01:48 Do patients on Pluvicto need to try a specific generation of hormone therapy?
02:57 Is chemotherapy still a prerequisite for starting Pluvicto?
03:30 How successful is Pluvicto at controlling prostate cancer?
04:59 Do any hormone therapies combine poorly with pluvicto?
06:07 What is the goal of combining Pluvicto and hormone therapy?
07:53 What quality of life impacts could this combination therapy have?
09:18 Alex's conclusions

Don't know your stage? Take the quiz: visit prostatecancerstaging.org


Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
Pluvicto Now Approved for Hormone-Sensitve #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRILupron + Xtandi Clinical Trial | #MarkScholzMD #PCRI #ProstateCancer2025 #PCRI Prostate Cancer Patients and Caregivers Conference #MarkScholzMD #MarkMoyadMDCan Gleason 6 #ProstateCancer Turn Into 7? | Jonathan Epstein, MD & Mark Moyad, MD, MPH #PCRIDealing with Anxiety & #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIAnswering Your #ProstateCancer Radiation Comments | #MarkScholzMD #AlexScholz #PCRIGenetic Testing & Biomarkers | 2025 Mid-Year Update | Todd Morgan, MD + Mark Moyad, MD Q&A #PCRIMRI & Active Surveillance for Gleason 6 (3+3) #MarkScholzMD #pcriHot Flashes From Hormone Therapy #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIMRI Surveillance & Gleason 6 (3+3)Optimal Duration of Hormone Therapy For #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIAnswering Your #ProstateCancer Active Surveillance Questions | #MarkScholzMD #AlexScholz #PCRI
Prostate Cancer Research Institute |

Pluvicto Now Approved for Hormone-Sensitve #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRI

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER